AutoGenomics Inc. filed papers by regulators for an initial public offering cost up to $86.3 million.

The 103-employee Carlsbad company, now incorporated in California, will reincorporate in Delaware before the IPO.

As its name suggests, AutoGenomics makes self-moving genetic tests for use in clinical laboratories. The Food and Drug Administration approved the Infiniti analyzer for sale in February 2007. As of June 30, some 58 of the devices were installed in various labs and hospitals, including San Francisco General Hospital.

Four of AutoGenomics' tests (out of 26 offered for appliance by the analyzer) are FDA approved, and the set plans to seek approval during the rest. The others can single be sold for research use, not for commercial testing.

The company has 18 salespeople around the United States. It sells its testing devices either instantly, or by a plan where the customer promises to buy a certain amount of consumable products from the company to pay for the system over confinement.

Some of the company's competitors include Abbott Laboratories, Celera, Nanosphere and Roche Diagnostics.

In the quarter ended March, AutoGenomics dreamy $3.1 the masses on sales of $185,161. At quarter's end the company had an accumulated deficit — how much it's lost since its start — of $34.3 million.

Fareed Kureshy, who started the company, is chairman, president and CEO. He worked 12 years at Abbott Laboratories. His 2008 lowest part salary is $350,000.

AutoGenomics started out in April 1999 as Neuron Technologies. It seeks to use the Nasdaq symbol AGMX.